The Chemours Company cash flow to debt ratio of 5.76% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

The Chemours Company's free cash flow has increased -105.14% from $-993.00M last year to $51.00M, signaling increasing performance

The Chemours Company's debt to equity ratio is 20.42, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

The Chemours Company's debt has increased relative to shareholder equity from 7.21 last year to 20.42 today, signaling weakened financials

The Chemours Company has a net debt to EBITDA ratio of 11.79x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

The Chemours Company's interest coverage ratio is -0.07, which means that the company struggles to meet interest obligations, signaling financial risk.

The Chemours Company's profit margin has decreased (-574.70%) in the last year from 1.49% to -7.06%, signaling decreasing performance

The Chemours Company's short-term assets of $3.00G exceed its short-term liabilities of $1.69G

The Chemours Company's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

The Chemours Company's return on equity of -164.40%, is lower than 15.00%, indicating bad performance

The Chemours Company's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

The Chemours Company had positive net income in 3.00 out of 5 years, indicating stable and consistent earnings

The Chemours Company has positive free cash flow, indicating the company generates cash after capital expenditures

The Chemours Company has a free cash flow yield of 1.82%, which is below the 2.00% threshold, indicating limited cash return relative to market value

The Chemours Company's yearly earnings has decreased -548.84% since last year from $86.00M to $-386.00M, signaling decreasing performance

The Chemours Company's yearly revenue has increased 0.45% since last year from $5.78G to $5.81G, signaling increasing performance

ROIC -0.33% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

The Chemours Company's 3-year revenue CAGR of -5.26% is negative, indicating declining revenue over the past 3 years

The Chemours Company had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

The Chemours Company had positive ROE in 3.00 out of 5 years, indicating consistent and reliable returns on equity

The Chemours Company has insufficient data to evaluate this check.

The Chemours Company has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

The Chemours Company is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

The Chemours Company has an EV/EBITDA ratio of 20.22x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

The Chemours Company is undervalued relative to its fair value price of 39.44 based on Earnings Fair Value model

The Chemours Company has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

The Chemours Company has a price-to-book ratio of 12.97x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

The Chemours Company has a price-to-sales ratio of 0.48x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue